India, May 31 -- Revolution Medicines, Inc. (RVMD) unveiled pivotal Phase 3 results from its RASolute 302 trial of Daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma, showing unprecedented survival gains compared to chemotherapy. The data were presented in a late-breaking plenary session at ASCO 2026 and simultaneously published in The New England Journal of Medicine.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, often diagnosed late and resistant to standard therapies. For patients who progress after first-line treatment, second-line chemotherapy typically offers modest benefit. In this global, randomized trial of 500 patients, once-daily oral Daraxonrasib reduced the risk of death by...